Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

European Journal of Endocrinology

Volumn 171, Issue 4, 2014, Pages 527-533

  Wenhui, Zhao ^a   Shuo, Li ^a   Dabei, Tang ^a   Ying, Piao ^a   Zhipeng, Wang ^a   Lei, Zhong ^a   Xiaohui, He ^a   Jingshu, Geng ^a   Hongtao, Song ^a   Qingyuan, Zhang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MASTECTOMY; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMISTRY; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS, MALE; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84907201010     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0278     Document Type: Article

References (29)

1. Sasco AJ, Lowenfels AB & Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case control studies and discussion of selected etiologic factors. International Journal of Cancer 1993 53 538-549. (doi:10.1002/ijc.2910530403)
2. Jemal A, Siegel R, Xu J & Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010 60 277-300. (doi:10.3322/caac.20073)
3. Hultborn R, Hanson C, Kopf I, Verbiene I, Warnhammar E & Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Research 1997 17 4293-4297.
4. Misra SP, Misra V & Dwivedi M. Cancer of the breast in a male cirrhotic: is there an association between the two? American Journal of Gastroenterology 1996 91 380-382.
5. Hsing AW, McLaughlin JK, Cocco P, Co Chien HT & Fraumeni JF Jr. Risk factors for male breast cancer (United States). Cancer Causes & Control 1998 9 269-275. (doi:10.1023/A:1008869003012)
6. Hill A, Yagmur Y, Tran KN, Bolton JS, Robson M & Borgen PI. Localized male breast carcinoma and family history. An analysis of 142 patients. Cancer 1999 86 821-825. (doi:10.1002/(SICI)1097-0142(19990901)86:5 !821::AID-CNCR18O3.0.CO;2-I)
7. Giordano SH, Buzdar AU & Hortobagyi GN. Breast cancer in men. Annals of Internal Medicine 2002 137 678-687. (doi:10.7326/0003-4819-137-8-200210150-00013)
8. Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N & Shapiro DH. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Modern Pathology 2002 15 853-861. (doi:10.1097/01.MP. 0000022251.61944.1D)
9. Nilsson C, Koliadi A, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, Hedenfalk I & Fjällskog M-L. High proliferation is associated with inferior outcome in male breast cancer patients. Modern Pathology 2013 26 87-94. (doi:10.1038/modpathol.2012.145)
10. Teller MN, Stock CC, Stohr G, Merker PC, Kaufman RJ, Escher GC & Bowie M. Biologic characteristics and chemotherapy of 7,12-dimethylbenz( a)anthracene-induced tumors in rats. Cancer Research 1966 26 245-252.
11. Toth-Fejel S, Cheek J, Calhoun K, Muller P & Pommier RF. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Archives of Surgery 2004 139 50-54. (doi:10.1001/archsurg.139.1.50)
12. Pich A, Margaria E, Chiusa L, Candelaresi G & Dal Canton O. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. British Journal of Cancer 1999 79 959-964. (doi:10.1038/sj.bjc.6690153)
13. Munoz de Toro MM, Maffini MV, Kass L & Luque EH. Proliferative activity and steroid hormone receptor status in male breast carcinoma. Journal of Steroid Biochemistry and Molecular Biology 1998 67 333-339. (doi:10.1016/S0960-0760(98)00124-1)
14. Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D & Mackiewicz A. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clinical Cancer Research 2003 9 4452-4459.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 2000 92 205-216. (doi:10.1093/jnci/92.3.205)
16. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology 2010 16 2784-2795. (doi:10.1200/JCO.2009.25.6529)
17. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clinical Oncology 2013 31 3997-4013. (doi:10.1200/JCO.2013.50.9984)
18. Czene K, Bergqvist J, Hall P & Bergh J. How to treat male breast cancer? Breast 2007 16 S147-S154. (doi:10.1016/j.breast.2007.07.024)
19. Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M & Fjällskog ML. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women -a population based study (Sweden). Acta Oncologica 2011 50 1083-1088. (doi:10.3109/0284186X.2011.602114)
20. Yang L, Sun TT & Wang N. The incidence and mortality trends of female breast cancer in Beijing, China: between 2004 and 2008. Zhonghua Yu Fang Yi Xue Za Zhi 2012 46 1009-1014. (doi:10.3760/cma.j.issn.0253-9624.2012.11.011)
21. Giordano SH, Cohen DS, Buzdar AU, Perkins G & Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004 101 51-57. (doi:10.1002/cncr.20312)
22. Kraus TS, Cohen C & Siddiqui MT. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagnostic Pathology 2010 5 63. (doi:10.1186/1746-1596-5-63)
23. Kidwai N, Gong Y, Sun X, Deshpande CG, Yeldandi AV, Rao MS & Badve S. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Research 2004 6 R18-R23. (doi:10.1186/bcr733)
24. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, Hinrichs B & van Diest PJ. Immunophenotyping of male breast cancer. Histopathology 2012 61 1145-1155. (doi:10.1111/j.1365-2559.2012.04330.x)
25. Anke Bergmann, Marcelo Adeodato Bello, Celia Regina Andrade Costa, Paulo Francisco Mascarenhas Bender, Luiz Claudio Santos Thuler. Male breast cancer: Overall survival in a single institution. Meeting: 2012 Breast Cancer Symposium, 2012.
26. Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Critical Review in Oncology and Hematology 2010 73 246-254. (doi:10.1016/j.critrevonc.2009.04.002)
27. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer. Breast Cancer Research and Treatment 2010 121 1-11. (doi:10.1007/s10549-009-0436-8)
28. PanPanet-Raymond V, Gottlieb B, Beitel LK, Pinsky L & Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Molecular and Cellular Endocrinology 2000 167 139-150. (doi:10.1016/S0303-7207 (00)00279-3)
29. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A & Auricchio F. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Research 2005 65 10585-10593. (doi:10.1158/0008-5472.CAN-05-0912)